Key result
Circulating sACE2 levels did not differ between severe and non-severe COVID-19 patients, suggesting it is not a useful prognostic biomarker.
Why the study?
Tools are urgently needed to help clinicians evaluate and manage high-risk COVID-19 patients, motivating investigation into whether sACE2 can serve as a prognostic biomarker.
Do circulating levels of sACE2 predict disease severity in COVID-19 patients?
Meta-Analysis
Do circulating levels of sACE2 predict disease severity in COVID-19 patients?
Circulating levels of ACE2 cannot be used as a reliable biomarker to assess disease severity in COVID-19 patients.
Answers are grounded in this paper and cite their sources.
sACE2 levels show no association with COVID-19 severity; leaves open its prognostic value in other contexts or with serial measurement.
BACKGROUND: The recently emerged novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has posed a serious threat to public health, and there is an urgent need to establish tools that can aid the clinician in the evaluation and management of highrisk patients. This meta-analysis aimed to investigate the potential of sACE2 (soluble angiotensinconverting enzyme 2) as a prognostic biomarker in COVID-19. METHODS: A comprehensive search of PubMed/MEDLINE, Cochrane, and Google Scholar, was performed until May 26, 2021. Data extraction and quality assessment of the study were independently conducted by the authors. Finally, 6 studies were included in this meta-analysis. RESULTS: ACE-2 serum or plasma levels were compared between COVID-19 patients and healthy controls. ACE-2 level was not significantly different between severe COVID-19 patients and healthy controls (SMD = 1.2; 95% CI: -1.3-1.5; P = 0.86), severe and non-severe COVID-19 patients (SMD = 0.3; 95% CI: -0.06-0.7; P = 0.1), and severe COVID-19 patients and healthy controls (SMD = 0.6; 95% CI: -1.1-2.3; P = 0.5). CONCLUSIONS: We cautiously propose that circulating levels of ACE2 cannot be used as a biomarker to assess disease severity in COVID-19 patients.
No takes yet. Share an insight, caveat, or question.
Rahimzadeh et al. (2022) conducted a meta-analysis in COVID-19. sACE2 (soluble angiotensin-converting enzyme 2) levels vs. Non-severe COVID-19 patients and healthy controls was evaluated on ACE-2 serum or plasma levels (severe vs non-severe COVID-19) (SMD 0.3, 95% CI -0.06-0.7, p=0.1). Circulating sACE2 levels did not differ between severe and non-severe COVID-19 patients, suggesting it is not a useful prognostic biomarker.
Synapse has enriched 10 related papers. Consider them for comparative context: